| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.005 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.15 | 0.006 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.23 | 0.007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.16 | 0.008 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.008 |